Literature DB >> 7829399

Improvement of macrophage dysfunction by administration of anti-transforming growth factor-beta antibody in EL4-bearing hosts.

H Maeda1, S Tsuru, A Shiraishi.   

Abstract

An experimental therapy for improvement of macrophage dysfunction caused by transforming growth factor-beta (TGF-beta) was tried in EL4 tumor-bearing mice. TGF-beta was detected in cell-free ascitic fluid from EL4-bearers, but not in that from normal mice, by western blot analysis. The ascites also showed growth-suppressive activity against Mv1Lu cells, and the suppressive activity was potentiated by transient acidification. To investigate whether the functions of peritoneal macrophages were suppressed in EL4-bearers, the abilities to produce nitric oxide and tumor necrosis factor-alpha (TNF-alpha) upon lipopolysaccharide (LPS) stimulation were measured. Both abilities of macrophages in EL4-bearing mice were suppressed remarkably on day 9, and decreased further by day 14, compared with non-tumor-bearing controls. TGF-beta activity was abrogated by administration of anti-TGF-beta antibody to EL4-bearing mice. While a large amount of TGF-beta was detected in ascitic fluid from control EL4-bearers, little TGF-beta was detectable in ascites from EL4-bearers given anti-TGF-beta antibody. Furthermore, while control macrophages exhibited little or no production of nitric oxide and TNF-alpha on LPS stimulation in vitro, macrophages from EL4-bearers administered with anti-TGF-beta antibody showed the same ability as normal macrophages. These results clearly indicate that TGF-beta contributes to macrophage dysfunction and that the administration of specific antibody for TGF-beta reverses macrophage dysfunction in EL4-bearing hosts.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7829399      PMCID: PMC5919362          DOI: 10.1111/j.1349-7006.1994.tb02919.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  33 in total

1.  Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta.

Authors:  M R Young; M A Wright; M Coogan; M E Young; J Bagash
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state.

Authors:  T Tada; S Ohzeki; K Utsumi; H Takiuchi; M Muramatsu; X F Li; J Shimizu; H Fujiwara; T Hamaoka
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

3.  Spontaneous production of a suppressor factor by the human macrophage-like cell line U937. I. Suppression of interleukin 1, interleukin 2, and mitogen-induced blastogenesis in mouse thymocytes.

Authors:  H Fujiwara; J J Ellner
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

4.  Transforming growth factor type beta induces monocyte chemotaxis and growth factor production.

Authors:  S M Wahl; D A Hunt; L M Wakefield; N McCartney-Francis; L M Wahl; A B Roberts; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

5.  A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.

Authors:  G Torre-Amione; R D Beauchamp; H Koeppen; B H Park; H Schreiber; H L Moses; D A Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

6.  Effects of transforming growth factor-beta 1 on human pulmonary adenocarcinoma cell adhesion, motility, and invasion in vitro.

Authors:  D L Mooradian; J B McCarthy; K V Komanduri; L T Furcht
Journal:  J Natl Cancer Inst       Date:  1992-04-01       Impact factor: 13.506

7.  Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells.

Authors:  C W Czarniecki; H H Chiu; G H Wong; S M McCabe; M A Palladino
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

8.  Modification of host antitumor defense mechanisms in mice by progressively growing tumor.

Authors:  D L Maccubbin; K F Mace; M J Ehrke; E Mihich
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

9.  Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.

Authors:  J H Kehrl; A B Roberts; L M Wakefield; S Jakowlew; M B Sporn; A S Fauci
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

10.  Potentiation of metastatic capacity by transforming growth factor-beta 1 gene transfection.

Authors:  N Ueki; T Ohkawa; Y Yokoyama; J Maeda; Y Kawai; T Ikeda; Y Amuro; T Hada; K Higashino
Journal:  Jpn J Cancer Res       Date:  1993-06
View more
  3 in total

1.  Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production.

Authors:  Saori Fujita-Sato; Shuichiro Ito; Takashi Isobe; Takao Ohyama; Kenji Wakabayashi; Kaoru Morishita; Osamu Ando; Fujio Isono
Journal:  J Biol Chem       Date:  2011-07-06       Impact factor: 5.157

2.  MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.

Authors:  P Mukherjee; A R Ginardi; C S Madsen; T L Tinder; F Jacobs; J Parker; B Agrawal; B M Longenecker; S J Gendler
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

3.  Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.

Authors:  Africa Wallace; Veena Kapoor; Jing Sun; Paul Mrass; Wolfgang Weninger; Daniel F Heitjan; Carl June; Larry R Kaiser; Leona E Ling; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.